These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 20008849)

  • 1. Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.
    Banck MS; Grothey A
    Clin Cancer Res; 2009 Dec; 15(24):7492-7501. PubMed ID: 20008849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.
    Custodio A; Feliu J
    Crit Rev Oncol Hematol; 2013 Jan; 85(1):45-81. PubMed ID: 22647972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer.
    Van Cutsem E
    Oncologist; 2006 Oct; 11(9):1010-7. PubMed ID: 17030643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
    Modjtahedi H; Essapen S
    Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular markers in the treatment of metastatic colorectal cancer.
    Wilson PM; Labonte MJ; Lenz HJ
    Cancer J; 2010; 16(3):262-72. PubMed ID: 20526105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies.
    Scartozzi M; Bearzi I; Berardi R; Mandolesi A; Fabris G; Cascinu S
    J Clin Oncol; 2004 Dec; 22(23):4772-8. PubMed ID: 15570078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New strategies for treatment of KRAS mutant metastatic colorectal cancer.
    Prenen H; Tejpar S; Van Cutsem E
    Clin Cancer Res; 2010 Jun; 16(11):2921-6. PubMed ID: 20460490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of molecular biomarkers in individualized treatment of colorectal cancer.
    De Mattos-Arruda L; Dienstmann R; Tabernero J
    Clin Colorectal Cancer; 2011 Dec; 10(4):279-89. PubMed ID: 21729679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer.
    Bouché O; Beretta GD; Alfonso PG; Geissler M
    Cancer Treat Rev; 2010 Feb; 36 Suppl 1():S1-10. PubMed ID: 20189053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer.
    Ramos FJ; Macarulla T; Capdevila J; Elez E; Tabernero J
    Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S52-7. PubMed ID: 19064407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Targeted biotherapy: a revolution in the management of patients with colorectal cancer?].
    Rougier P; Mitry E
    Gastroenterol Clin Biol; 2009; 33(8-9):672-80. PubMed ID: 19717258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colorectal cancer in review: the role of the EGFR pathway.
    Saif MW
    Expert Opin Investig Drugs; 2010 Mar; 19(3):357-69. PubMed ID: 20095919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancer.
    Sobani ZA; Sawant A; Jafri M; Correa AK; Sahin IH
    World J Clin Oncol; 2016 Oct; 7(5):340-351. PubMed ID: 27777877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating biomarkers into clinical decision making for colorectal cancer.
    Wilson PM; Lenz HJ
    Clin Colorectal Cancer; 2010 Jun; 9 Suppl 1():S16-27. PubMed ID: 20630847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liquid biopsy to detect resistance mutations against anti-epidermal growth factor receptor therapy in metastatic colorectal cancer.
    Valenzuela G; Burotto M; Marcelain K; González-Montero J
    World J Gastrointest Oncol; 2022 Sep; 14(9):1654-1664. PubMed ID: 36187383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colorectal Cancer: From Genetic Landscape to Targeted Therapy.
    El Bali M; Bakkach J; Bennani Mechita M
    J Oncol; 2021; 2021():9918116. PubMed ID: 34326875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Profiling of EGFR Status to Identify Skin Toxicity in Colorectal Cancer: A Clinicopathological Review.
    Popa CM; Lungulescu C; Ianoși SL; Cherciu I; Schenker M; Săftoiu A
    Curr Health Sci J; 2019; 45(2):127-133. PubMed ID: 31624638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Markers of resistance to anti-EGFR therapy in colorectal cancer.
    Shaib W; Mahajan R; El-Rayes B
    J Gastrointest Oncol; 2013 Sep; 4(3):308-18. PubMed ID: 23997942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF p.Val600Glu (V600E) Testing for Assessment of Treatment Options in Metastatic Colorectal Cancer.
    Lea A; Allingham-Hawkins D; Levine S
    PLoS Curr; 2010 Oct; 2():RRN1187. PubMed ID: 20972475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update in antiepidermal growth factor receptor therapy in the management of metastatic colorectal cancer.
    Loong HH; Ma BB; Chan AT
    J Oncol; 2009; 2009():967920. PubMed ID: 19365583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.